The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAnimal health specialist Virbac released its annual financial results for 2025, demonstrating resilient performance amid operational challenges. The company achieved organic revenue growth of 7.9% at constant exchange rates and scope (CERS). The adjusted EBIT margin reached 16.3%, a solid figure considering temporary production shutdowns and inventory write-offs. Growth was primarily driven by a 5% contribution from volume and product mix, supplemented by a 3% increase from price adjustments. Strong momentum across key product categories and geographic regions helped offset the impact of one-off operational setbacks. These results highlight Virbac's robust underlying business performance and its ability to maintain healthy margins.